FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival

Christopher Lieu

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.

Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs.

As a gastrointestinal oncologist and researcher specializing in early-phase clinical trials, I have seen the critical need for more effective therapies for patients with pancreatic cancer. For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible.

However, that narrative is rapidly changing with a drug approved on Aug. 26, 2026, that can shut down the key protein that drives pancreatic cancer, nearly doubling survival rates for patients with advanced stages of the...

Read More

Postpartum psychosis: A psychiatrist explains

NBC 4 Washington

A Boston-area mother who killed her three young children was suffering from postpartum psychosis, her defense argues. Psychiatrist Dr. Joshua Weiner explains what the rare condition is. “Trust your gut” if you think you need help, he said in conversation with News4’s Eun Yang.

Watch the video HERE.